管理胰岛素抵抗:2型糖尿病中被遗忘的病理生理环节
本文指出GLP-1受体激动剂虽能通过减重降糖并保护心血管,却不能使2型糖尿病合并肥胖者的胰岛素敏感性正常化,且对肌肉量、衰弱和骨密度的长期影响研究不足。噻唑烷二酮类是唯一真正的直接胰岛素增敏药,但因副作用未广泛使用。作者认为开发可与GLP-1受体激动剂联用的强效胰岛素增敏药仍是重大未满足需求。
要点
- GLP-1受体激动剂不能使2型糖尿病合并肥胖者的胰岛素敏感性正常化。
- 噻唑烷二酮类是唯一真正的直接胰岛素增敏药,但因副作用未广泛使用。
- 开发可与GLP-1受体激动剂联用的强效胰岛素增敏药仍是重大未满足需求。
核心结论
- 胰岛素抵抗在2型糖尿病病因及动脉粥样硬化性心血管疾病发病机制中起重要作用,开发可与GLP-1受体激动剂联用的强效胰岛素增敏药仍是2型糖尿病管理中的重大未满足需求。
研究设计与样本
- 本文为Lancet Diabetes Endocrinol发表的综述,检索范围原文未报告。
主要发现
- GLP-1受体激动剂因强效减重、增强β细胞功能和心血管保护作用而广泛用于2型糖尿病治疗。
- 尽管GLP-1受体激动剂带来显著减重,却不能使2型糖尿病合并肥胖者的胰岛素敏感性正常化。
- GLP-1受体激动剂对肌肉量、衰弱和骨密度的长期影响研究不足。
- GLP-1受体激动剂通过减重间接改善胰岛素敏感性,而噻唑烷二酮类是唯一真正的直接胰岛素增敏药。
- 噻唑烷二酮类因与2型糖尿病治疗相关的副作用而未广泛使用。
关键数值与推荐
- 原文未报告具体数值标准或推荐条款。
临床怎么用
- 原文未据此给出推荐。
局限性
- GLP-1受体激动剂对肌肉量、衰弱和骨密度的长期影响研究不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucagon-like peptide-1 (GLP-1) receptor agonists have gained widespread use in the treatment of individuals with type 2 diabetes because of their potent weight loss promoting effect, ability to augment β-cell function, and cardiovascular protective effects. However, despite causing impressive weight loss, GLP-1 receptor agonists do not normalise insulin sensitivity in people with type 2 diabetes and obesity, and the long-term effects of this class of antidiabetic medication on muscle mass, frailty, and bone density have been poorly studied. Although GLP-1 receptor agonists improve insulin sensitivity secondary to weight loss, the only true direct insulin-sensitising drugs are thiazolidinediones. Because of side-effects associated with type 2 diabetes therapy, these drugs have not gained widespread use. In lieu of the important role of insulin resistance in the cause of type 2 diabetes and in the pathogenesis of atherosclerotic cardiovascular disease in type 2 diabetes, development of potent insulin-sensitising drugs that can be used in combination with GLP-1 receptor agonists remains a large unmet need in the management of individuals with type 2 diabetes.
引用
- Abdul-Ghani M, Maffei P, DeFronzo RA, et al. Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes. Lancet Diabetes Endocrinol. 2024. PMID: 39098317. doi:10.1016/S2213-8587(24)00127-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。